|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine C-C chemokine receptor 4 (CCR4) expression as a diagnostic and therapeutic biomarker in CD8+ CTCLs/LPDs.
|
31355940 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
None of the other covariates-for example, age, body weight, body mass index, bilirubin, creatinine clearance, disease type (ATL and CTCL), ATL subtype (acute, lymphoma, and chronic), CTCL subtype (mycosis fungoides and Sézary syndrome), CCR4 expression (status or degree), race (Japanese and non-Japanese), renal impairment (normal, mild, moderate, and severe), or performance status-had a statistically significant impact.
|
31840838 |
2020 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
|
31322628 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CCR4 is expressed in almost all cases of ATLL, and in a majority of CTCLs, particularly when blood involvement is present.
|
30799938 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that differential patterns of CXCR3, CCR3, CCR4 and CCR10 expression are useful for the diagnosis of cutaneous T-cell lymphoma.
|
31045236 |
2019 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When we examined the CCR4 expression in skin samples from primary cutaneous T-cell lymphoma, obtained from the same patients before and after vorinostat treatment, we found that CCR4 expression was greatly reduced after treatment.
|
29025909 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the large international phase III MAVORIC trial, patients with previously treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody mogamulizumab experienced significantly longer progression-free survival and higher response rates, as well as better quality of life, than those who received vorinostat, a standard therapy.
|
29298770 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mogamulizumab (Mog) is a defucosylated, therapeutic monoclonal antibody, targeting CCR4 and was first approved in Japan for the treatment of adult T-cell leukaemia/lymphoma (ATLL), followed by cutaneous T-cell lymphoma and peripheral T-cell lymphoma.
|
29341283 |
2018 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peripheral blood of 24 patients with CTCL participating in a phase I/II trial was analyzed for CCR4 expression on different T-cell subsets by flow cytometry, before and after one course of mogamulizumab.
|
25376389 |
2015 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results, thus, demonstrate the presence of a common oncogenic cascade initiated by FRA2/JUND in CCR4-expressing mature T-cell malignancies such as ATLL and CTCLs.
|
22493372 |
2012 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, a xenograft model of CTCL was established and a recombinant adeno-associated viral serotype 8 (AAV8) vector expressing a humanized single-chain variable fragment (scFv)-Fc fusion (scFvFc or "minibody") of anti-CCR4 monoclonal antibody (mAb) h1567 was evaluated for curative treatment.
|
22973452 |
2012 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, treatment with the thymus and activation-regulated chemokine (CCL17)-expressing chemotoxin efficiently eradicated CCR4-expressing cutaneous T cell lymphoma/leukemia established in NOD-SCID mice.
|
17641067 |
2007 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the expression of CCR4, CCR7 and CCR10 on skin-homing CLA(+) and CD4(+) T cells in the peripheral blood of patients with Sezary syndrome (SS), a rare leukaemic variant of cutaneous T-cell lymphoma.
|
15727636 |
2005 |
|
Lymphoma, T-Cell, Cutaneous
|
0.100 |
Biomarker
|
disease |
LHGDN |
T cells expressing CLA and CCR4 were also found at high levels in cutaneous T cell lymphoma lesions along with abundant expression of the two CCR4 ligands TARC/CCL17 and MDC/CCL22.
|
12485447 |
2002 |